Skip to Content
  • Idiocy On Drug Research Costs

    Here’s a piece from the Center for Economic and Policy Research that claims to have the whole high-drug-price problem figured out. It’s “incr… Read More
  • C-Nucleosides Never Went Away

    Here’s a paper in J. Med. Chem. calling for a revival of work in the C-nucleoside area. To some extent, these compounds never went away, but it’s ce… Read More
  • A Biotech Education, In Progress

    Peter Thiel is worth paying some attention to. And it’s not just because he’s a wealthy venture capitalist – his views on pharma and biotech r… Read More
  • That One Big Answer

    This post by Wavefunction on the foxes-and-hedgehogs split in drug discovery is well worth reading. You may recall, via Isaiah Berlin and Archilochus, that a fo… Read More
  • ABT-199 Nears Its Finish Line

    A couple of years back, AbbVie ran into an unusual problem in the clinic. Their Bcl ligand, ABT-199, was working a bit too well, and killing off so many leukemi… Read More
  • Celgene Expanding

    Readers who have worked in the NJ pharma world will be familiar with the big research campus in Summit. I go back far enough to remember it from my first round… Read More
  • Are Things Really Picking Up?

    Is the recent upturn in drug approvals the real thing? Years of overall decline would have to be overcome, but it would be good news if the industry has, in fac… Read More
Page 5 of 39« First...34567...102030...Last »